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Summary
OBJECTIVE: To evaluate the rates of penicillin, clindamy-
cin and erythromycin resistance and the serotype distribu-
tion among isolates of group B streptococcus (GBS) ob-
tained from pregnant women at the University Hospital of
Bern in Switzerland.
METHODS: We prospectively collected screening samples
for GBS colonisation at the University Women’s Hospital
Bern, Switzerland, between March 2009 and August 2010.
We included 364 GBS isolates collected from vaginal, cer-
vical or vaginal-perianal swabs at any gestation time. The
minimal inhibitory concentrations for penicillin, clindamy-
cin and erythromycin were established using Etest with 24
hours of incubation, and inducible clindamycin resistance
was tested with double disk diffusion tests. Serotyping was
done with a rapid latex agglutination test or, if not con-
clusive, with polymerase chain-reaction (PCR) testing. We
looked for significant associations between resistance pat-
terns, age groups, serotype and ethnicity.
RESULTS: All isolates were susceptible to penicillin.
Resistance rates were 14.5% for erythromycin and 8.2%
for clindamycin. Of 364 isolates, 5.8% were susceptible
to clindamycin but not to erythromycin, although demon-
strating inducible clindamycin resistance. Hence, the final
reported clindamycin resistance rate was 14%. Serotype
III was the most frequent serotype (29%), followed by V
(25%) and Ia (19%). Serotype V was associated with eryth-
romycin resistance (p = 0.0007). In comparison with all
other ethnicities, patients from Asia showed a higher pro-
portion of erythromycin and clindamycin resistance (p =
0.018). No significant association between resistance pat-
terns and age groups was found.
CONCLUSION: In pregnant women with GBS colonisa-
tion, penicillin is the antibiotic of choice for intrapartum
prophylaxis to prevent neonatal early-onset GBS sepsis. In
women with penicillin allergy and at high risk for ana-
phylactic reaction, clindamycin may be an alternative. The
resistance rate for clindamycin at our institution was 14%;
therefore, susceptibility must be tested before administra-
tion.
Key words: group B streptococcus; maternal GBS
colonisation; antimicrobial susceptibility
Introduction
Streptococcus agalactiae, or group B streptococcus (GBS),
is a common cause of neonatal sepsis and meningitis. The
pathogenesis of these infections is based on GBS colonisa-
tion in the maternal genital tract and on the transmission of
the microorganism from the mother to the neonate [1]. The
GBS colonisation rate varies between countries, ranging
from 6.5% to 36% [2]. The prevalence of anogenital GBS
maternal carriage at our centre was 21% [3]. Without in-
trapartum antimicrobial prophylaxis, the peripartum trans-
mission to the newborn is estimated to be 50% to 70% [2,
4], resulting in a high frequency of early-onset GBS sepsis.
With the introduction of a strategy of maternal screening
for GBS carriage and the practice of administering intra-
partum chemoprophylaxis to colonised mothers, the incid-
ence of neonatal early onset sepsis was significantly re-
duced in many countries [5–7].
GBS isolates are commonly susceptible to penicillin.
Therefore, the recommendation for intrapartum prophylax-
is is to administer intravenous penicillin every 4 hours un-
til delivery [6]. However, there are some worrisome reports
on reduced penicillin susceptibility in GBS [8–11].
In GBS-colonised mothers with allergy and low risk of ana-
phylaxis to penicillin, the use of cefazolin is recommen-
ded. In those with a high risk of anaphylaxis to penicillin,
clindamycin (if the isolate is susceptible) or vancomycin (if
the isolate is resistant to clindamycin) is recommended [6].
In our hospital, the risk of anaphylaxis is mainly evaluated
on the patient history and the reported host reaction after a
previous exposure to a penicillin-derivate. The risk is con-
sidered low if there are no signs of an immunoglobulin E
(IgE) mediated reaction (e.g., exanthema, drug fever). The
risk is considered high if there are indicators for an IgE-me-
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diated reaction (e.g., anaphylactic shock, bronchospasm,
angioedema, larynx oedema or Quincke’s oedema).
Published frequencies of erythromycin- and clindamycin-
resistant strains range from 7% to 16% and 3% to 9%, re-
spectively [12, 13]. There are, however, geographical vari-
ations in resistance rates [14]. In one study that tested 200
GBS isolates collected from vaginal/rectal specimens, the
resistance rate was 54% for erythromycin and 33% for
clindamycin [15]. The local rates of resistance to clinda-
mycin have a significant impact on the use of antibiotics
administered to women with a high risk for anaphylaxis to
penicillin.
The aim of this study was to evaluate the rates of penicillin,
clindamycin and erythromycin resistance among GBS isol-
ates obtained from pregnant women at the University Hos-
pital of Bern in Switzerland. Given the interesting reports
showing an association between erythromycin resistance
and serotype V [16–20], we also analysed the serotype dis-
tribution among our isolates.
Material and methods
The GBS screening was conducted at the University Wo-
men’s Hospital Bern, Switzerland. At our centre, universal
screening for GBS is performed in all pregnant women
between weeks 35–37 of gestation [3]. As this study fo-
cussed on the epidemiology of antimicrobial resistance pat-
terns and serotype distribution among pregnant women, we
included all GBS isolates irrespective of gestation time.
The isolates were collected via a vaginal, cervical or
vaginal-perianal swab. The sampling period started in
March 2009 and ended in August 2010. The sampling was
performed consecutively, and one isolate per patient was
included in the analysis. In the case of multiple sampling
from the same individual, the GBS isolate that was closest
to the 35th–37th week of gestation was used for analysis.
The minimal inhibitory concentrations (MICs) for penicil-
lin, clindamycin and erythromycin were determined with
Etest (bioMérieux, Marcy l’Etoile, France). Interpretation
of results is based on the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) recommenda-
tions for broth microdilution [21]. Inducible resistance to
clindamycin (i-clind-R) was assessed with a double disk
diffusion test [22, 23]. Serotyping was performed by use of
a rapid latex agglutination test (Strep-B-Latex kit, Statens
Serum Institut, Copenhagen, Denmark) [24]. Nontypeable
strains were examined by polymerase chain-reaction (PCR)
analysis [25].
We looked for significant associations between resistance
patterns and ethnicity, age groups and serotypes. Prior to
the laboratory tests, the variables were defined. Isolates
with i-clind-R were considered as clindamycin nonsuscept-
ible. Ethnicity was categorised in patients from Western
Europe, Eastern Europe, Africa, South America, Asia and
Middle East. Age groups were categorised as 20–29 years,
30–39 and ≥40 years old.
GraphPad Prism 5.0 was used for statistical analysis. Dif-
ferences in group proportions were assessed by contin-
gency tables and the chi-square test, or Fisher’s exact prob-
ability test if a frequency was smaller than 5. For direct
comparison a 2 x 2, and for distribution analysis a 6 x 2, 3
x 2, or 10 x 2 contingency tables, respectively, were used.
A two-tailed p-value of ≤0.05 was considered significant.
Results
During the screening period, we collected 364 GBS isol-
ates. The susceptibility patterns of the tested antibiotics are
presented in figure 1. All isolates were susceptible to peni-
cillin. The penicillin MIC of most ranged from 0.012 to
0.064 μg/ml. Twelve of the 364 isolates (3.3%) showed an
MIC of 0.094 μg/ml and only one isolate (0.3%) revealed
an MIC of 0.125 µg/ml. A total of 53 (14.6%) isolates were
not susceptible to erythromycin, 27 of them (27/53, 50.9%)
had a MIC of ≥256 µg/mL. A total of 30 (8.2%) of the
364 isolates were not susceptible to clindamycin. In ad-
dition, 21 isolates (5.8%) that were considered clindamy-
cin susceptible in the Etest were i-clind-R when tested by
the double disk diffusion test (table 1). Hence, clindamycin
could not be recommended as an alternative antimicrobial
regimen to penicillin in 14% of the patients (51/364) with
proven GBS colonisation.
All GBS isolates could be designated to a serotype. Sero-
type III was the most frequent serotype (107/364, 29.4%),
followed by V (93/364, 25.5%) and by Ia (70/364, 19.2%).
Figure 1
Minimum inhibitory concentration distributions of penicillin,
clindamycin and erythromycin.
Clinical breakpoints according to European Committee on
Antimicrobial Susceptibility Testing (EUCAST) are indicated by a
vertical line. Penicillin susceptible ≤0.25 µg/ml, erythromycin
susceptible ≤0.25 µg/ml, clindamycin susceptible ≤0.5 µg/ml.
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We then analysed the association between erythromycin
and clindamycin resistance (table 1). A total of 85% of the
isolates (309/364, 84.9%) were susceptible to both clinda-
mycin and erythromycin. On the other hand, 7.7% (28/364)
of the isolates were neither susceptible to clindamycin nor
to erythromycin. Thus, there was a discrepancy between
clindamycin and erythromycin susceptibility in 7.4% isol-
ates (27/364). In 92.6% (25/27) of them, the isolates were
susceptible to clindamycin, but not to erythromycin.
Though, in 21 of these 25 GBS isolates, there was an
i-clind-R, and hence, a typical inducible macrolide-
lincosamide-streptogramin B (MLSB) phenotype. Only 4
isolates showed an M phenotype. Of note, the M phenotype
is attributed to isolates that are susceptible to clindamycin
but not to erythromycin and do not reveal an i-clind-R. The
postulated mechanism conferring to this phenotype are act-
ive drug efflux pumps encoded by mef genes [26]. Taken
together, in 92.5% ([28 + 21 = 49]/53) of the erythromycin
nonsusceptible isolates, clindamycin could not be recom-
mended.
We then analysed the association between resistance pat-
terns and origin, age groups and serotypes (table 2). Most
of our patients (238/364, 65.4%) were from western
European countries. In comparison to all other ethnicities,
patients from Asia showed a higher proportion of erythro-
mycin resistance (37.5% vs 13.5%, p = 0.018). However,
the overall statistical distribution among areas of origin
was not significant (6 x 2 contingency table). We did not
find an association between age groups and clindamycin or
erythromycin resistance rates. However, the serotype distri-
bution and the resistance to clindamycin and erythromycin
showed a significant association (10 x 2 contingency table).
In the univariate analysis, the strongest association was
found with serotype V and erythromycin resistance (69/
311, 22.2% erythromycin susceptible vs 24/53, 45.3% non-
susceptible, p = 0.0007). The associations with serotype Ia
and clindamycin susceptibility (p = 0.033), and serotype II
with both clindamycin and erythromycin susceptibility (p =
0.043 and 0.026, respectively), were based on small abso-
lute numbers (n <5).
Discussion
At our institution, GBS isolates were uniformly susceptible
to penicillin [6, 13, 14, 27, 28]. Hence, penicillin is the
compound of choice for intrapartum prophylaxis.
The question of an alternative antimicrobial compound
arises when a patient reports an allergy to penicillin. In
clinical practice, it is often difficult to distinguish the extent
of the allergic reaction. This may particularly be the case
under stressed circumstances (e.g., delivery). Therefore, it
is important to clarify the type of allergy prior to delivery.
We prospectively collected GBS from colonised women
and analysed the clindamycin resistance rate. We looked
for variables that were associated with resistance patterns,
thereby intending to identify factors that may influence the
choice of an antimicrobial compound in the case of un-
known resistance patterns (e.g., late screening, preterm de-
livery).
We found rates of resistance to erythromycin (14.5%) and
clindamycin (14.0%) comparable to those reported in other
studies published in Europe [14]. However, a recent study
from Geneva found higher resistance rates (clindamycin
28%, erythromycin 30%) [29]. This illustrates that there
are regional differences even within the same country. In
our study, cross-resistance to clindamycin (either con-
stitutive or inducible) was found in 49 isolates (92.5%) of
the erythromycin nonsusceptible strains (n = 53). There-
fore, in GBS isolates that are not susceptible to erythro-
mycin, resistance to clindamycin should be suspected until
proven otherwise. If only the clindamycin Etest (incubation
for 24 hours) and no double disk testing is performed, an
i-clind-R can remain undetected. Clindamycin would then
be reported as susceptible (which is not correct). Accord-
ing to the manufacturer's instructions, an i-clind-R can be
detected by Etest, if results are interpreted after 48 hours of
incubation. In our view, double disk testing is more estab-
lished and efficient in routine laboratory work.
The clinical relevance of inducible MLSB-resistance (i-
clind-R) is better known in staphylococci than in beta-hae-
molytic streptococci. The microorganisms show a high rate
of spontaneous mutation to constitutive resistance. Con-
ceivably, they are selected under clindamycin therapy, and
hence there are reports of treatment failure [30–33].
Whether this phenotype has clinical significance in intra-
partum prophylaxis for GBS-colonised women is not clear.
However, guidelines recommend considering inducible
MLSB phenotype of GBS to be clindamycin resistant [6,
34].
GBS can be further characterised by its serotype. Serotypes
III, V and Ia were the most frequent serotypes. Interest-
ingly, these serotypes are found in almost 70% of the in-
vasive cases. However, the serotype distribution of both
invasive and colonising strains is continuously evolving
and demonstrates not only regional but also temporal vari-
ation [35]. Previous observations reported an association
between erythromycin resistance and serotype V [16]. This
was confirmed in our study as well.
Table 1: Association between erythromycin and clindamycin resistance.
Total Clindamycin susceptible*
n = 313
Clindamycin susceptible* but i-clind-R±
n = 21
Clindamycin nonsusceptible*
n = 30
Erythromycin susceptible n = 311 309 (99.4%1/84.9%2) ‒ 2 (0.6%1/0.5%2)
Erythromycin nonsusceptible n = 53 4§ (7.5%1/1.1%2) 21¶ (39.6%1/5.8%2) 28 (52.8%1/7.7%2)
i-clind-R = inducible clindamycin resistance.
Nonsusceptible isolates consisted of intermediate and resistant isolates.
*Susceptibility determined by Etest for 24 hours.
± Inducible clindamycin resistance was tested by the double disk diffusion test.
§ M phenotype (i.e., clindamycin susceptible, erythromycin nonsusceptible).
¶ Inducible MLSB phenotype.
1 Proportion calculated with denominator being the total number of erythromycin susceptible (311) or nonsusceptible isolates (53), respectively.
2 Proportion calculated with denominator being the total number of isolates included in the study (364).
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We analysed whether or not there is an association between
ethnicity and antibiotic resistance patterns. Chohan et al.
[36] found that prevalence of clindamycin or erythromycin
resistance was higher among Caucasian women than
among African-American and Hispanic women. On the
other hand, Manning et al. [18] reported that black ethnicity
was associated with higher clindamycin resistance. In our
population, African, South American and Asian patients
represented a minority. Although patients from Asia had a
higher proportion of erythromycin and clindamycin resist-
ance, which may point towards high resistance rates in Asi-
an countries [37], it is important to note that the absolute
number was small.
In conclusion, penicillin is the antibiotic of choice for intra-
partum GBS prophylaxis. Women who are allergic to peni-
cillin should be questioned and evaluated about the extent
of their allergy. In case of a relevant reaction after a pre-
vious exposure to penicillin or its derivate, they should re-
ceive either cefazolin or vancomycin depending on the risk
of developing an anaphylactic reaction. If clindamycin is
an option, it must be tested prior to delivery. Each institu-
tion should periodically perform resistance surveillance of
their GBS isolates [38]. Susceptibility testing of GBS isol-
ated from pregnant women must include the double disk
diffusion test for the detection of i-clind-R. In our view, the
resistance rates of 14.5% and 14%, respectively, do not al-
low administration of clindamycin empirically if GBS col-
onisation is proven.
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Figures (large format)
Figure 1
Minimum inhibitory concentration distributions of penicillin, clindamycin and erythromycin.
Clinical breakpoints according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) are indicated by a vertical line.
Penicillin susceptible ≤0.25 µg/ml, erythromycin susceptible ≤0.25 µg/ml, clindamycin susceptible ≤0.5 µg/ml.
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